First U.S. Patients Receive Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara

Telix Pharmaceuticals announced that the first patients in the United States have been dosed with Pixclara® (floretyrosine F 18), its FDA-approved amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging. This milestone marks the commercial availability of Pixclara, which is indicated to help physicians differentiate recurrent or progressive glioma from treatment-related changes in adult and pediatric patients aged one month and older.